BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6968751)

  • 1. The active site of C3a anaphylatoxin.
    Caporale LH; Tippett PS; Erickson BW; Hugli TE
    J Biol Chem; 1980 Nov; 255(22):10758-63. PubMed ID: 6968751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The active site of human C4a anaphylatoxin.
    Hugli TE; Kawahara MS; Unson CG; Molinar-Rode R; Erickson BW
    Mol Immunol; 1983 Jun; 20(6):637-45. PubMed ID: 6603573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.
    Hugli TE; Erickson BW
    Proc Natl Acad Sci U S A; 1977 May; 74(5):1826-30. PubMed ID: 266705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active site of C3a anaphylatoxin: contributions of the lipophilic and orienting residues.
    Unson CG; Erickson BW; Hugli TE
    Biochemistry; 1984 Feb; 23(4):585-9. PubMed ID: 6608957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and partial characterization of human and porcine C3a anaphylatoxin.
    Hugli TE; Vallota EH; Müller-Eberhard HJ
    J Biol Chem; 1975 Feb; 250(4):1472-8. PubMed ID: 803505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide.
    Lu ZX; Fok KF; Erickson BW; Hugli TE
    J Biol Chem; 1984 Jun; 259(12):7367-70. PubMed ID: 6610676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.
    Gerard C; Hugli TE
    Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1833-7. PubMed ID: 6940191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and function of the anaphylatoxins.
    Hugli TE
    Springer Semin Immunopathol; 1984; 7(2-3):193-219. PubMed ID: 6387982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release.
    Glovsky MM; Hugli TE; Ishizaka T; Lichtenstein LM; Erickson BW
    J Clin Invest; 1979 Sep; 64(3):804-11. PubMed ID: 89118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential.
    Burger R; Zilow G; Bader A; Friedlein A; Naser W
    J Immunol; 1988 Jul; 141(2):553-8. PubMed ID: 2454995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of casoxin C, an ileum-contracting peptide derived from bovine kappa-casein, as an agonist for C3a receptors.
    Takahashi M; Moriguchi S; Suganuma H; Shiota A; Tani F; Usui H; Kurahashi K; Sasaki R; Yoshikawa M
    Peptides; 1997; 18(3):329-36. PubMed ID: 9145417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C4a: the third anaphylatoxin of the human complement system.
    Gorski JP; Hugli TE; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5299-302. PubMed ID: 291947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helical conformation at the carboxy-terminal portion of human C3a is required for full activity.
    Hoeprich PD; Hugli TE
    Biochemistry; 1986 Apr; 25(8):1945-50. PubMed ID: 3486674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contraction of guinea pig lung by synthetic oligopeptides related to human C3a.
    Huey R; Erickson BW; Bloor CM; Hugli TE
    Immunopharmacology; 1984 Aug; 8(1):37-45. PubMed ID: 6333413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
    Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
    Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The primary structure of porcine C3a anaphylatoxin.
    Corbin NC; Hugli TE
    J Immunol; 1976 Sep; 117(3):990-5. PubMed ID: 956663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of humoral immune responses by synthetic C3a peptides.
    Morgan EL; Weigle WO; Erickson BW; Fok KF; Hugli TE
    J Immunol; 1983 Nov; 131(5):2258-61. PubMed ID: 6355293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification, characterization, and amino acid sequence of rat anaphylatoxin (C3a).
    Jacobs JW; Rubin JS; Hugli TE; Bogardt RA; Mariz IK; Daniels JS; Daughaday WH; Bradshaw RA
    Biochemistry; 1978 Nov; 17(23):5031-8. PubMed ID: 309768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary injury induced by C3a and C5a anaphylatoxins.
    Stimler NP; Hugli TE; Bloor CM
    Am J Pathol; 1980 Aug; 100(2):327-48. PubMed ID: 6967702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.
    Fernandez HN; Hugli TE
    J Biol Chem; 1978 Oct; 253(19):6955-64. PubMed ID: 690134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.